Medicine and Dentistry
Gallium 68
100%
Prostate Cancer
76%
Non Muscle Invasive Bladder Cancer
76%
Positron Emission Tomography
73%
Biological Marker
69%
Prostate Specific Membrane Antigen
69%
Bladder Cancer
50%
Neutrophil
46%
Lymph Node Metastasis
46%
Polyethylene Terephthalate
46%
Lymphocyte
46%
Decision Making
36%
Urology
34%
Metastatic Carcinoma
33%
Diagnosis
28%
Cystectomy
25%
Prostatectomy
24%
Recurrent Disease
24%
Systemic Therapy
23%
Biochemical Recurrence
23%
Hospital Management
23%
Germinoma
23%
Body Mass Index
23%
Seasonal Variation
23%
Cancer Prognosis
23%
Ureter Stone
23%
Clinical Significance
23%
Patient Selection
23%
Cancer Registry
23%
Meta-Analysis
23%
Systematic Review
23%
Cytoreductive Surgery
23%
Diagnostic Performance
23%
Biodistribution
23%
Androgen Deprivation Therapy
23%
Circulating Tumor DNA
23%
Cross Sectional Study
23%
Morphology
23%
Colonoscopy
23%
Urolithiasis
23%
Kidney Stone
23%
Enfortumab Vedotin
23%
Conjugate
21%
Nephrostomy
17%
Neoplasm
15%
Risk Stratification
15%
Magnetic Resonance Imaging
11%
Hydronephrosis
11%
Muscle Invasive Bladder Cancer
11%
Polyp
11%
Dietary Supplement
11%
Urinary Diversion
11%
Percutaneous Nephrolithotomy
11%
Diseases
11%
Transitional Cell Carcinoma
10%
Progression Free Survival
10%
Tumor Diagnosis
9%
Logistic Regression Analysis
9%
Patient Counseling
7%
Carcinogenesis
7%
Personalized Medicine
7%
PET-MRI
7%
Radiation Therapy
7%
Randomized Controlled Trial
7%
Prevalence
7%
Hazard Ratio
7%
Consultation
7%
Diagnostic Accuracy
7%
Disease Course
7%
Physical Activity
7%
Therapy Planning
7%
Awareness
7%
Urothelial Cancer
7%
Therapeutic Management
7%
Seminoma
6%
Salivary Gland
6%
Proportional Hazards Model
6%
Malignant Neoplasm
6%
Overall Survival
5%
Cancer Diagnosis
5%
Obstruction
5%
Positron Emission Tomography-Computed Tomography
5%
Side Effect
5%
Lymph Node
5%
DNA Determination
5%
Pharmacology, Toxicology and Pharmaceutical Science
Polyethylene Terephthalate
92%
Gallium 68
79%
Prostate Cancer
76%
Biological Marker
49%
Non Muscle Invasive Bladder Cancer
46%
Prostate Specific Membrane Antigen
46%
Neoplasm
30%
Ureter Stone
23%
Biochemical Recurrence
23%
Lymphocyte Antigen Receptor
23%
Biodistribution
23%
Antigen
23%
Cancer Prognosis
23%
Kidney Stone
23%
Nephrolithiasis
23%
Tracer
23%
Lymph Node Metastasis
23%
Cross-Sectional Study
23%
Circulating Tumor DNA
23%
Lutetium 177
23%
Radioligand
23%
Enfortumab Vedotin
23%
Dietary Supplement
11%
Recurrent Disease
7%
Malignant Neoplasm
6%
Obstruction
5%